Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Continuing Forward With Innovation and Progress in US Healthcare
May 22, 2017
Dr Gail Wilensky: Senate Health Bill Will Be to the Left of the House
May 22, 2017
Accounting for Stakeholder Preferences in Value Assessments
May 22, 2017
Dr David M. Cutler Highlights the Importance of Reauthorizing the CHIP Program
May 22, 2017
Negotiating Successful Outcomes-Based Contracts
May 23, 2017
Dr Ilene Hollin: Tailored Approach to Value Assessment Is Necessary
May 23, 2017
Influencing Untreated Individuals Through Their Social Networks
May 23, 2017
Dr Steve Pearson Outlines the Importance of Thresholds on Determining Value
May 23, 2017
The Realities and Challenges of Medicare Negotiating Drug Prices
May 24, 2017
Dr Patricia Danzon: Cost-Effectiveness Thresholds Create Incentive to Develop Better Drugs
May 24, 2017
Gene Therapies Present Great Potential, but Also Ethical and Practicality Challenges
May 24, 2017
Dr James D. Chambers Talks Future Health Economics Trends He Is Watching
May 24, 2017
Dr Gail Wilensky Remains "Hopeful" for Bipartisan Legislation on Healthcare Reform
May 29, 2017
Dr David Cutler: Won't Be Easy for Senate Republicans to Create a Healthcare Bill
May 30, 2017
Not Enough Attention Paid to Low Healthcare Spending Growth
June 13, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Steve Pearson: Patient Perspectives Guide ICER Value Framework Development
July 04, 2017
Currently Reading
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017

Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations

Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.


Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.

Transcript (slightly modified)

Do you think the country’s trajectory over the past few years toward value-based care will continue under the new administration?

I think we are on value-based care as where we need to be going forward, no matter who is running the administrations. We’re not quite as advanced as we like to talk about it. Most of the people who are doing value-based care strategies still reimburse their physicians using fee-for-service, which is not particularly compatible with value-based care, so we’re talking a little better game than we’re actually doing, but I don’t see us moving backward from where we are. It’s a question of how fast, how aggressively we’ll move forward to being really serious about purchasing value-based care.

What impact do you think HHS Secretary Tom Price, MD, will have on new payment model pilots?

The question about whether Dr Price, Secretary Price now, will pull back from pilots has been raised a lot. I think what he is likely to move away from are the mandatory demonstrations, which had been raised at the end of the Obama administration, and which have an appeal in that they don’t have to contend with self-selection as an issue. But I’m not sure they’re as critical as they’re sometimes made out to be.

His point, and I have some sympathy with this, is that by having large-scale, mandatory demonstrations, you’re basically taking away the right of Congress to make changes in reimbursement, and that, more than potentially limited mandatory demonstrations or voluntary demonstrations, is what he was pushing against, as well as the other Republican members of the Congress.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up